Jun Sugama
Fujisawa, 2518555, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
First clinical demonstration of sustained insulin-like growth factor 1 elevation via oral somatostatin receptor 5 antagonism: a phase 1 trial of SCO-240.
Journal: European journal of endocrinology
Published: April 07, 2026
Oral SSTR5 Antagonist SCO-240 for Growth Hormone Stimulation: A Phase I Single-Dose Study in Healthy Individuals.
Journal: Clinical pharmacology and therapeutics
Published: September 20, 2023
Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity.
Journal: Pharmacology research & perspectives
Published: August 24, 2022
An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria.
Journal: Kidney international reports
Published: May 31, 2022
Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Journal: The Journal of pharmacology and experimental therapeutics
Published: June 07, 2021
Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice.
Journal: Pharmacological research
Published: September 20, 2020
Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: June 29, 2020
Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease.
Journal: Diabetes, obesity & metabolism
Published: June 10, 2020
SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.
Journal: Diabetes, obesity & metabolism
Published: February 26, 2019
Discovery of novel somatostatin receptor subtype 5 (SSTR5) antagonists: Pharmacological studies and design to improve pharmacokinetic profiles and human Ether-a-go-go-related gene (hERG) inhibition.
Journal: Bioorganic & medicinal chemistry
Published: May 09, 2017
Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus.
Journal: Bioorganic & medicinal chemistry
Published: May 09, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026